MiR-503 inhibits the G1/S transition by downregulating cyclin D3 and E2F3 in hepatocellular carcinoma [57], it inhibits cell proliferation and invasion in glioma by targeting L1CAM [58], it targets PI3K p85 and IKK-β and suppresses the progression of non-small-cell lung cancer [58], and it inhibits cellular proliferation by targeting the AKT2 3′-UTR region in cervical cancer [59]. Here, E2F3 is linked to central nervous system cancer.